The GLP-1 receptor is expressed in vivo by human metastatic prostate cancer

Stein, MS; Kalff, V; Williams, SG; Murphy, DG; Colman, PG; Hofman, MS

Author(s): Stein, MS; Kalff, V; Williams, SG; Murphy, DG; Colman, PG; Hofman, MS;
Details: Publication Year 2024-01-01,Volume 4,Issue #1,Page e230015
Journal Title: Endocrine Oncology
Publication Type: Research article
Abstract: OBJECTIVES: The glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, reduces human prostate cancer incidence, and similar GLP-1 receptor agonists reduce in vitro proliferation and in vivo growth of prostate cancer cell lines. Primary human prostate cancer expresses the GLP-1 receptor (GLP-1R) in vitro. Cancer evolves with stage, and whether advanced-stage human prostate cancer expresses GLP-1R is unknown. We hypothesised and aimed to prove that human metastatic castrate-resistant prostate cancer (mCRPC) expresses the GLP-1R in vivo. We hypothesised that mCRPC would thus be detectable by positron emission tomography/computed tomography (PET/CT) using a radiotracer bound to a GLP-1R ligand, as in exendin PET/CT. MATERIALS AND METHODS: Men with mCRPC, with more than one prostate-specific membrane antigen (PSMA)-avid lesion on PET/CT scanning (pathognomic in that setting for prostate cancer lesions), were approached to undergo PET/CT with gallium(68)-Dota-exendin-4. We documented PET/CT PSMA-avid lesions, which were also PET/CT exendin avid, as evidence of in vivo GLP-1R expression. RESULTS: Out of the 24 men referred, three did not meet the inclusion criteria. Seventeen declined, largely because the study offered them no therapeutic benefit. Among the four men imaged, three had no exendin-avid lesions, while one had six osseous PSMA-avid lesions, three of which were also exendin avid. CONCLUSIONS: We demonstrated in vivo GLP-1R expression by human mCPRC, detecting PET/CT lesions avid for both PSMA and exendin, in one of four participants. GLP-1R expression may thus occur even in advanced-stage prostate cancer. Our data contribute to growing evidence supporting the testing of GLP-1 receptor agonists for therapeutic benefit in prostate cancer.
Publisher: Bioscientifica
Keywords: PET scan; exenatide; glucagon-like peptide 1 (GLP-1); prostate cancer
Department(s): Cancer Imaging; Radiation Oncology; Surgical Oncology
Publisher's Version: https://doi.org/10.1530/eo-23-0015
Open Access at Publisher's Site: https://doi.org/10.1530/eo-23-0015
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-03-26 02:32:39

Last Modified: 2024-03-26 02:56:13